EYEGENE
EYEGENE
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2000-06-23
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.eyegene.co.kr
Total Employee:
51+
Status:
Active
Contact:
82 2 322 1687
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Content Delivery Network Font Awesome Apache Mobile Non Scaleable Content JsDelivr
Similar Organizations
Aposcience AG
Aposcience AG is a biopharmaceutical company.
Xanthus Pharmaceuticals
Xanthus is a biopharmaceutical company.
Official Site Inspections
http://www.eyegene.co.kr Semrush global rank: 4.77 M Semrush visits lastest month: 1.94 K
- Host name: 211.47.74.55
- IP address: 211.47.74.55
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "EyeGene"
EYEGENE Inc.
ABOUT EYEGENE. Clinical stage biopharmaceutical developing vaccines and new innovative recombinant protein drugs. EyeGene took its first step in the development of innovative biopharmaceutical drugs when it was first โฆSee details»
Wonil Yoo๋ - CEO - EyeGene, inc. | LinkedIn
CEO at EyeGene, Inc. · ABOUT EYEGENE Clinical stage biopharmaceutical developing vaccines and new innovative recombinant protein drugs EyeGene โฆSee details»
EYEGENE Inc. Company Profile | Seoul, Seoul, Republic Of Korea ...
Find company research, competitor information, contact details & financial data for EYEGENE Inc. of Seoul, Seoul. Get the latest business insights from Dun & Bradstreet.See details»
EyeGene - Crunchbase Investor Profile & Investments
Eyegene.co.kr ; 42,146; Highlights. Investments 1. Investors 1. Similar Companies 5. ... Legal Name EyeGene Inc. Company Type For Profit; Phone Number 82 2 322 1687; Lists Featuring โฆSee details»
EyeGene, Inc. Company Profile - South Korea | Financials & Key
Jul 5, 2024 EyeGene, Inc. is a company located in Seoul, South Korea. It was established in June 2000 as Igene Co., Ltd. and focuses on bio-drug development to address the challenges โฆSee details»
EyeGene, Inc. - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... EyeGene, Inc. Booth 2464. โฆSee details»
EYEGENE Inc.
EyeGene has established a network through strong alliances with University Hospitals. Further networks have been established with Yonsei Universityโs proteomics research laboratory, Yonsei University Medical Centerโs โฆSee details»
EyeGene (KOSDAQ:185490) Company Profile & Description
Apr 15, 2025 Company profile for EyeGene Inc. (KOSDAQ:185490) with a description, list of executives, contact details and other key facts.See details»
EyeGene, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.eyegene.co.kr. Last update 07 Mar 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The statistics for โฆSee details»
EYEGENE.Inc Annual Report - englishdart.fss.or.kr
[email protected]: Disclosure Contact: SH, Chai: Deputy General Manager: 02-322-1687: 02-302-4359: [email protected]: Form Information. Consolidated Financial โฆSee details»
Eyegene - Overview, News & Similar companies | ZoomInfo.com
Oct 4, 2021 Eyegene contact info: Phone number: +82 23221687 Website: www.eyegene.co.kr What does Eyegene do? EyeGene took its first step in the development of innovative โฆSee details»
EyeGene Inc. Company & People | 185490 - Barron's
EyeGene Inc. company and executive profile by Barron's. View the latest 185490 company infomation and executive bios. ... Shanghai Hile Bio-Technology Co. Ltd. A. 2.27 % ¥4.74B. โฆSee details»
EYEGENE Inc.
๊ถ์ ์ข ์์ด์ง ์ฐ๊ตฌ์์ฅ โํ๊ตญํ ๋ชจ๋๋ ํ์ ์ฃผ๋ํ ๊ฒโ [ 2024๋ 11์ 11์ผ - ์ด๋ฐ์ผ๋ฆฌ ] ์์ด์ง ์ฃผ์ํ์ฌ์ ๊ถ์ ์ข ๋ฐ์ฌ๋ ์ง๋ 9์, ์ฐ๊ตฌ์์ฅ์ ์ ์๋์์ผ๋ฉฐ ์์ผ๋ก ์ 2์ ํฌ๋ฐ๋ฏน์ ๋๋นํ โฆSee details»
EyeGene initiates strategic R&D overhaul with BMI Korea โฆ
Dec 14, 2023 EyeGene, a messenger ribonucleic acid (mRNA) vaccine developer, has ushered in BMI Korea as its new largest shareholder.The company is drawing attention by announcing โฆSee details»
EuBiologics license out EuMCV4 meningococcal vaccine to โฆ
Jul 3, 2024 Eyegene is a Korean biotech firm developing vaccines against shingles, tuberculosis, and Covid-19 using its own adjuvant platform technology. The agreement follows EuBiologics' โฆSee details»
Kukje, Eyegene to co-develop non-proliferative diabetic ... - KBR
Jun 12, 2023 Kukje Pharm said Monday that it has signed an agreement with Eyegene to co-develop EG-Mirotin, the world's first treatment for non-proliferative diabetic retinopathy. โฆSee details»
EYEGENE Inc.
T. +82-2-322-1687 f. +82-2-302-4359 / +82-2-324-8059 ๋ณธ์ฌ : [16009] ๊ฒฝ๊ธฐ๋ ์์์ ์์งํธ2๋ก 13, 2์ธต (์ฒญ๊ณ๋, ํ๊ตญ๋น์ ์์ด ๋น๋ฉ) ์ฐ๊ตฌ์ : [16009] ๊ฒฝ๊ธฐ๋ ์์์ ์์งํธ2๋ก 7, 4์ธต (์ฒญ๊ณ๋, โฆSee details»
EyeGene-EyeGene Inc.-ไผไธ่ฏฆๆ -InvestGOๆฐๆฎๅบ-ByDrug-ๅป่ฏ้ญ โฆ
Dec 31, 1999 ๆฅ็ๅป่ฏ้ญๆนInvestGO®ๆฐๆฎๅบEyeGene็ๅ ฌๅธไฟกๆฏใEyeGene๏ผEyeGene Inc.๏ผ๏ผๅ ฌๅธ็ฎไป๏ผEyeGene, Inc. is a Korean Proteomics & Biopharmaceutical Bio-Venture โฆSee details»
EYEGENE Inc.
Established EyeGene, Inc. T. +82-2-322-1687; F. +82-2-302-4359 / +82-2-324-8059; ๋ณธ์ฌ : [16009] ๊ฒฝ๊ธฐ๋ ์์์ ์์งํธ2๋ก 13, 2์ธต (์ฒญ๊ณ๋, ํ๊ตญ๋น์ ์์ด ๋น๋ฉ) ์ฐ๊ตฌ์ : [16009] ๊ฒฝ๊ธฐ๋ โฆSee details»
EYEGENE Inc.
EyeGene R&D Center was officially authorized in May 2001 and has been dedicated to developing innovative biopharmaceuticals, vaccines, and diagnostic system for the treatment โฆSee details»